Navigation Links
Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
Date:5/6/2008

HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Jane Green, Kosan's Vice President, Corporate Communications, will present at the Leerink Swann Solid Tumors Roundtable Conference in New York at the Grand Hyatt Hotel on Friday, May 9, 2008 at 11:10 a.m. EDT. A live webcast of the presentation can be accessed through http://www.wsw.com/webcast/leerink15/kosn/.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentations will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
4. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
5. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
6. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
7. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
8. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
9. Kosan Announces February 28, 2008 Conference Call and Webcast
10. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
11. Kosan Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... , ... The European Patent Office (EPO) today announced that ... the European Inventor Award 2016 in the category "Non-European countries." The winners of the ... in Lisbon on June 9th. , The human capacity to walk with fluidity is ...
Breaking Biology Technology:
(Date:3/9/2016)... 9, 2016  Crossmatch ® , a leading ... today announced the addition of smart features to ... multi-factor authentication platform. New contextual and application-specific authentication ... security where it,s needed most — while minimizing ... . --> Washington, DC ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
(Date:3/1/2016)... FRANCISCO , March 1, 2016  (RSAC Booth ... year, but a whopping $118 billion is lost to ... to overzealous and inaccurate fraud detection. At the RSA ... in the way companies handle authentication by devaluing the ... and behavioral analytics. --> ...
Breaking Biology News(10 mins):